Back to discover
Drug

Tenecteplase

Established medicine
ResearchOngoing research
Also known as TNK, TNK-tPA, TNKase, rhTNK-tPA+1 more

TNK, TNK-tPA, TNKase, rhTNK-tPA, Tenecteplasa.

RxNorm259280UNIIWGD229O42W
1
Research papers
1
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Impact of Thrombolytic Therapy on the Long-Term Outcome of Intermediate-Risk Pulmonary Embolism.

Research2017-03-01Konstantinides SV · Journal of the American College of Cardiology

Approval: Metalyse (EMA)

Regulatory2001-02-23EMA

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Tenecteplase
Aliases & brands
TNKTNK-tPATNKaserhTNK-tPATenecteplasa
RxNorm CUI
259280
UNII
WGD229O42W
Regulatory jurisdictions
ema

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval
2001-02-23
Latest approval
2001-02-23
Authorities
EMA
Total events
1
emaEuropean Medicines Agency· 1 event
2001-02-23Approval
Approval: Metalyse (EMA)
Indication: Metalyse is indicated for the thrombolytic treatment of suspected myocardial infarction with persistent ST elevation or recent left-bundle-branch block within six hours after the… Show full indication

Metalyse is indicated for the thrombolytic treatment of suspected myocardial infarction with persistent ST elevation or recent left-bundle-branch block within six hours after the onset of acute-myocardial-infarction symptoms. Metalyse is indicated in adults for the thrombolytic treatment of acute ischaemic stroke (AIS) within 4.5 hours from last known well and after exclusion of intracranial haemorrhage.

Evidence ↗

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Most influential

Impact of Thrombolytic Therapy on the Long-Term Outcome of Intermediate-Risk Pulmonary Embolism.

Journal of the American College of Cardiology · 2017 · 226 cites
Recent papers

Impact of Thrombolytic Therapy on the Long-Term Outcome of Intermediate-Risk Pulmonary Embolism.

Journal of the American College of Cardiology · 2017 · 226 cites
Major research themes1
Thrombolytic Therapy1
Journals, researchers & institutions
Top journals
  • Journal of the American College of Cardiology1
Leading researchers
  • Becattini C1
  • Bertoletti L1
  • Beyer-Westendorf J1
  • Bouvaist H1
  • Couturaud F1
  • Danays T1
  • Dellas C1
  • Duerschmied D1
Leading institutions
free-text, unnormalised
  • and German Center for Cardiovascular Research (DZHK)1
  • Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona1
  • Bologna University Hospital1
  • Ca Foncello Hospital1
  • Cardiology and Pulmonology Clinic1
  • Center for Thrombosis and Hemostasis1
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • Europe PMC — research literature
  • Regulatory event sources are credited in the Regulatory Timeline above.